Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from
cure in> 90% of patients with low risk disease to< 50% for those with high risk disease …

Approximately half of the patients diagnosed with neuroblastoma are classified as having
high-risk disease. This group continues to have inadequate cure rates despite multiagent …

The disialoganglioside GD2 is overexpressed on several solid tumors, and monoclonal
antibodies targeting GD2 have substantially improved outcomes for children with high-risk …

Genetic studies have established anaplastic lymphoma kinase (ALK), a cell surface receptor
tyrosine kinase, as a tractable molecular target in neuroblastoma. We describe …

Purpose Anti-GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage
colony-stimulating factor (GM-CSF) has shown efficacy against neuroblastoma (NB) …

Activating mutations in the anaplastic lymphoma kinase (ALK) gene were recently
discovered in neuroblastoma, a cancer of the develo** autonomic nervous system that is …

Purpose: Anaplastic lymphoma kinase (ALK) is the most frequently mutated oncogene in the
pediatric cancer neuroblastoma. We performed an in vitro screen for synergistic drug …

Neuroblastoma, the most common extracranial pediatric solid tumor remains a clinical
enigma with outcomes ranging from cure in> 90% of patients with locoregional tumors with …

Purpose Platinum-based therapy is the mainstay for management of high-risk
neuroblastoma. Prevalence of platinum-related ototoxicity has ranged from 13% to 95% in …

Peripheral neuroblastic tumours (PNTs), a family of tumours arising in the embryonal
remnants of the sympathetic nervous system, account for 7–10% of all tumours in children. In …